HomeFilePharmacology

Pharmacology

View Category

Acute coronary syndromes

Post MI Betablockers for Good?

Patients receiving optimal medical treatment after MI do not seem to benefit from betablockers in the long...
solaci -
Learn More
Antiplatelet

Short Therapy and Monotherapy, Plenty of Evidence

A short dual antiplatelet therapy (DAPT) of 1 to 3 months followed by P2Y12 inhibitor monotherapy after...
solaci -
Learn More
Other

Diastolic Pressure Could Play a Dirty Trick on Patients Treated for Hypertension

Having too low diastolic pressure could be linked to an increase in cardiovascular events (J-shape phenomenon). However,...
solaci -
Learn More
Antithrombotic Anticoagulants

Major Cause of Myocardial Injury by COVID-19

The most common cause of myocardial necrosis in patient undergoing COVID-19 infection is microthrombi. These microthrombi resulted...
solaci -
Learn More
Antithrombotic Anticoagulants

AAS vs Warfarin in Low Risk TAVR

We are still discussing the adequate antithrombotic scheme after transcatheter aortic valve replacement (TAVR). Additionally, we are...
solaci -
Learn More
Chronic Ischemic cardiopathy

Medical Therapy Optimization Achieved Prior Clinical Trial

12 weeks prior the ORBITA randomization, medical therapy optimization of all antianginal medication was achieved.   Most importantly, optimization...
solaci -
Learn More
Antiplatelet

Net Clinical Benefit of Long-Term Ticagrelor

Ticagrelor reduces ischemic risk in patients with a history of acute myocardial infarction, but it increases the...
solaci -
Learn More
Chronic Ischemic cardiopathy

Regression of High-Risk Plaque with Lifestyle Changes

Diet and lifestyle intervention in addition to optimal medical therapy can slow down plaque building and even...
solaci -
Learn More